CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31

Cytek Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$5.25+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $679.67M
P/E (TTM): –
Dividend yield: –

Cytek Biosciences, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	201	200	193	164	2.18	0.71
Cost of Revenue	97	89	84	63	49	41
Gross Profit	104	111	109	101	79	52
Research & Development	36	39	44	35	24	14
Selling, General & Admin	108	92	93	68	46	24
Selling & Marketing	49	49	49	33	25	15
General & Administrative	59	43	44	35	21	9.37
Advertising Expenses	4.20	3.80	3.40	2.50	1.80	1.00
Operating Expenses	145	132	137	103	70	38
Operating Income	-40	-21	-28	-1.80	9.16	14
Interest Expense	0.47	-5.24	2.07	2.57	1.74	0.33
Interest & Investment Income	2.22	5.12	6.41	4.62	0.05	0.11
Other Non-Operating Income	11	15	12	3.06	-3.22	0.77
Gain (Loss) on Investments	–	–	0	0	0.04	0
Gain (Loss) on Sale of Assets	-0.42	-0.06	-0.01	0	0	–
Legal Settlements	-1.00	–	–	–	–	–
Pretax Income	-30	-5.70	-16	1.26	5.94	14
Income Tax Expense	37	0.32	-3.56	-1.22	2.91	-4.98
Net Income incl. Noncontrolling Interests	-67	-6.02	-12	2.48	3.03	19
Minority Interest in Earnings	0	0	0	-0.09	0.03	0
Net Income	-67	-6.02	-12	2.48	3.03	19
Net Income to Common	-67	-6.02	-12	2.58	0	3.22
EPS (Basic)(per share)	–	–	-0.09	0.02	0.00	0.11
EPS (Diluted)(per share)	–	–	-0.09	0.02	0.00	0.10
Shares Outstanding (Basic, Weighted)(shares)	128	131	135	135	77	29
Shares Outstanding (Diluted, Weighted)(shares)	128	131	135	139	82	33
EBITDA	-33	-13	-22	0.69	10	14

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 53.2%
Operating margin: -21.6%
Net margin: -32.2%
Return on equity, FY2025: -18.0%

Financial strength

Current ratio: 4.48
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 87.6%

Valuation

P/E ratio: –
Price to sales: 3.29
Price to book: 2.11
Dividend yield: –